Home › Drug Codes › Q Codes › Q5107 · MVASI
Updated July 1st, 2026

MVASI Q Code: Q5107

Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for Q5107, effective October 1, 2026: $28.294 per HCPCS billing unit, up 15.3% from $24.533. From CMS's final file.

?
Medicare Payment Limit ?
$24.533
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$24.533
/ HCPCS billing unit · APC 9329
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
4
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
HCPCS Added Date January 1, 2019
Manufacturer Amgen
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Solution

About MVASI

Mvasi is a medication aligned to the HCPCS Q Code: Q5107 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Amgen.

According to CMS Drug Use Information: This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-adcd, bevacizumab-awwb, bevacizumab-bvzr, bevacizumab-maly, and bevacizumab-nwgd.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
55513-0206-01 Mvasi Amgen, Inc 10 100 MG / 4 ML
55513-0206-21 Mvasi Amgen, Inc 10 100 MG / 4 ML
55513-0207-01 Mvasi Amgen, Inc 40 400 MG / 16 ML
55513-0207-21 Mvasi Amgen, Inc 40 400 MG / 16 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

MVASI Pricing & Reimbursement

Q5107 Private Payer Reimbursement
$25.84 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Bevacizumab Biosimilar Information:

MVASI Approval Date: September 14, 2017

Product Name HCPCS Code Active Ingredient BLA Type
Avastin J9035 Bevacizumab 351(a) Originator Product
Mvasi Q5107 Bevacizumab 351(k) Biosimilar
Zirabev Q5118 Bevacizumab 351(k) Biosimilar
Alymsys Q5126 Bevacizumab 351(k) Biosimilar
Vegzelma Q5129 Bevacizumab 351(k) Biosimilar
Avzivi N/A Bevacizumab 351(k) Biosimilar
Jobevne Q5160 Bevacizumab 351(k) Biosimilar

MVASI Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 15.62%
Avg. Days to File 11.0days
Avg. Days to Pay 25.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5107 claims analytics on FocalPoint →
OnPoint Oncology

MVASI CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
JW / JZ modifiers apply

CMS has identified Mvasi (Q5107) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

MVASI Medically Unlikely Edits (MUE)

The most billing units of Q5107 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient
230 units / day
= 2,300 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

MVASI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Metastatic Colorectal Cancer Metastatic Renal Cell Carcinoma Non-Squamous Non-Small Cell Lung Cancer Persistent, Recurrent, or Metastatic Cervical Cancer Recurrent Glioblastoma
Drug Class
Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available Mvasi billing and coding guide?
Billing and coding information for MVASI can be found through Amgen. Visit Here →
Are there any available Mvasi patient assistance programs?
MVASI patient assistance information can be found through Amgen. Visit Here →
Where can I find Mvasi prescribing information?
MVASI prescribing information can be found at the link below: Visit Here →
Where can I find Mvasi side effect information?
Information regarding MVASI's side effects can be found at MedlinePlus Visit Here →
Does billing MVASI require JZ/JW wastage modifiers?
CMS has identified MVASI(Q5107) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to MVASI.

J9035AVASTINInjection, bevacizumab, 10 mgGenentechAdded January 1, 2005Q5118ZIRABEVInjection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mgPfizerAdded October 1, 2019Q5126AlymsysInjection, bevacizumab-maly, biosimilar, (alymsys), 10 mgAmneal BiosciencesAdded January 1, 2023Q5129VegzelmaInjection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgCelltrion USAAdded April 1, 2023Q5160JOBEVNEInjection, bevacizumab-nwgd (jobevne), biosimilar, 10 mgBiocon Biologics IncAdded January 1, 2026C9257AVASTINInjection, bevacizumab, 0.25 mgGenentechAdded January 1, 2010C9310VykouraInjection, leucovorin calcium (avyxa), 1 mgAvyxa PharmaAdded July 1, 2026J0641FUSILEVInjection, levoleucovorin, not otherwise specified, 0.5 mgMultiple ManufacturersAdded January 1, 2009J0642KhapzoryInjection, levoleucovorin (khapzory), 0.5 mgAcrotech BiopharmaAdded October 1, 2019J0644VykouraInjection, leucovorin calcium (avyxa), 1 mgAvyxa PharmaAdded October 1, 2026